Advertisement
Canada markets closed
  • S&P/TSX

    24,072.51
    -30.20 (-0.13%)
     
  • S&P 500

    5,751.13
    +55.19 (+0.97%)
     
  • DOW

    42,080.37
    +126.13 (+0.30%)
     
  • CAD/USD

    0.7328
    -0.0014 (-0.19%)
     
  • CRUDE OIL

    73.90
    -3.24 (-4.20%)
     
  • Bitcoin CAD

    85,144.73
    -1,265.55 (-1.46%)
     
  • XRP CAD

    0.73
    -0.01 (-1.14%)
     
  • GOLD FUTURES

    2,640.60
    -25.40 (-0.95%)
     
  • RUSSELL 2000

    2,194.98
    +1.89 (+0.09%)
     
  • 10-Yr Bond

    4.0330
    +0.0070 (+0.17%)
     
  • NASDAQ futures

    20,286.25
    +293.50 (+1.47%)
     
  • VOLATILITY

    21.42
    -1.22 (-5.39%)
     
  • FTSE

    8,190.61
    -113.01 (-1.36%)
     
  • NIKKEI 225

    38,937.54
    -395.20 (-1.00%)
     
  • CAD/EUR

    0.6671
    -0.0017 (-0.25%)
     

Oaktree Capital raises stake in UK's Indivior, becomes 2nd largest shareholder

FILE PHOTO: Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration

(Reuters) - Investment fund Oaktree Capital Management has raised its stake in Indivior Plc to become its second largest shareholder, days after the British drugmaker issued a profit warning and signalled a slowdown in sales of its top-selling opioid addiction treatment.

Oaktree, which specialises in providing rescue funding to struggling firms, disclosed a 6.3% stake in Indivior, a filing showed on Friday.

Oaktree had a 2.5% stake in the drugmaker, according to LSEG data. Investment manager Two Seas Capital is the top shareholder with a nearly 10% ownership.

Indivior, which moved its primary listing to New York last month, has been facing intense competition in the United States for its opioid drug Sublocade from the launch of a rival, Brixadi.

The drugmaker said earlier this week it will discontinue sales of its schizophrenia drug Perseris, resulting in 130 job cuts.

(Reporting by Radhika Anilkumar in Bengaluru; Editing by Janane Venkatraman and Mrigank Dhaniwala)